drugset / Trial / NCT02182401

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

NCT02182401

Phase 1 Terminated 37 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to investigate the pharmacokinetic drug-drug interaction potential of BI 207127 NA and BI 201335 NA on each other at steady-state and to quantify the effect of BI 207127 NA, and BI 207127 NA combined with BI 201335 NA, on the activity of CYP 2C9 and CYP 3A4 using the probe substrates tolbutamide (CYP 2C9) and midazolam (CYP 3A4).

Timeline

Start
2009-07
Primary completion
2009-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Deleobuvir Small molecule
Subject Faldaprevir Small molecule
Subject Midazolam Small molecule
Subject Tolbutamide Small molecule

Indications

No indication recorded.